Insitu hybridization (fish)
CPT 88366 covers fluorescence in situ hybridization (FISH) testing, a specialized laboratory technique that uses fluorescent probes to detect specific DNA sequences in tissue or cell samples to diagnose genetic abnormalities, cancers, and chromosomal disorders.
This calculator gives a typical-case estimate using standard Medicare modifier rules. Actual payment depends on payer policies, documentation, code-specific CMS status indicators, and locality. Verify before billing.
RVU breakdown
Conversion factor: 32.3465 · Source: CMS MPFS RVU25A · Confidence: High
NCCI bundling edits
Loading bundling edits…
Billing tips
Bill 88366 per probe set, not per specimen - if testing uses multiple different probe sets on the same specimen, each probe set may be separately billable
Impact: Can increase reimbursement from $260.07 to $520.14 or more when multiple distinct probe sets are medically necessary and properly documented
Document the specific gene or chromosome target for each FISH probe used (e.g., HER2, ALK, BCR-ABL, chromosome 17) in the pathology report
Impact: Prevents 15-20% of medical necessity denials and supports billing multiple units when applicable
Verify that diagnostic code supports medical necessity for the specific FISH test ordered - many payers have local coverage determinations limiting which diagnoses qualify
Impact: Reduces denial rate by 25-30%; common issue with screening versus diagnostic testing distinctions
For reflex FISH testing (performed automatically based on initial findings), ensure ordering physician documentation supports medical necessity before specimen analysis
Impact: Prevents $260.07 denial for tests performed without explicit order or medical indication
When billing with other pathology codes on same specimen, check NCCI edits carefully - 88366 may bundle with certain comprehensive cytogenetic codes
Impact: Avoids automatic claim rejections and reduces appeals; bundling errors cause 10-15% of initial denials
For Medicare patients, verify that FISH is performed for FDA-approved or compendia-listed indications to meet national coverage determination requirements
Impact: Ensures Medicare reimbursement eligibility; non-covered indications result in 100% payment denial ($260.07 loss)
Real billers contribute denial patterns and appeal strategies for this code. Once 5+ reports come in, you’ll see live aggregated data here — the only place this exists, free.
Get the free Revenue Protection Toolkit — the denial triggers, modifier pitfalls, and bundling conflicts that quietly cost you reimbursement. Instant download.
Help build the field knowledge
MedPayIQ gets smarter as billers contribute. If you've had this code denied, share what happened so others learn from it. Anonymous, no patient info.